Solving Testing Challenges Through Collaboration and Action
Early in Vermont’s stay-at-home
order phase, the state faced both a
shortage of COVID-19 test materials
and limited capacity to process tests.
As the only medical school and level one trauma
center in Vermont, the Larner College of Medicine and
University of Vermont Medical Center, respectively,
quickly acted to address these challenges.
Between March and June, Larner scientists produced
more than 37,000 vials of solution for use in COVID-19
testing. UVM Vaccine Testing Center research technicians
took the lead in collecting transport media—a
solution needed for COVID-19 specimen collection—
from Larner laboratories. Then members of the UVM
Medical Center Department of Pathology and Laboratory
Medicine added swabs and other components
and assembled the kits. Deborah Leonard, M.D., Ph.D.,
chair of pathology and laboratory medicine, and Beth
Kirkpatrick, M.D., chair of microbiology and molecular
genetics and Vaccine Testing Center director, provided
leadership for the initiative.
With limited laboratory personnel to process
COVID-19 tests, Vermont turned to the Mayo Clinic
Laboratories for help. UVM pathology and laboratory
medicine staff were organizing daily transport
of tests samples from Boston’s Logan Airport to
Rochester, Minn., when they ran into a snag—flights
were getting cancelled, which meant test results and
important related clinical decisions were delayed. In
a demonstration of true community collaboration,
members of the medical center, UVM Health Network,
Vermont Department of Public Safety, Green Mountain
Messenger, JV Air LLC, and Heritage Flight rallied to
secure a private jet to make the deliveries, ensuring
24-hour turnaround test results. This arrangement
allowed Vermont to send up to 600 tests per day to
Mayo, says Leonard, which was two to three times as
many tests as Vermont had been previously sending.
An innovative research initiative, run concurrently
with the test assembly effort, brought Larner virologists,
pathologists, and infectious disease experts
together to evaluate potential alternatives to the traditional
RNA extraction kit, a key part of the COVID-19
testing process that has been in short supply. They
tried two strategies: An alternative RNA extraction
kit and an assay that omits an RNA extraction step
altogether. Associate Professor of Medicine Jason
Botten, Ph.D., Faculty Scientist Emily Bruce, Ph.D., and
colleagues published the initial findings as a BioRxiv
manuscript preprint. The experimental test has been
replicated by labs all over the world with promising results.
The team has since published a second preprint,
a peer-reviewed article, and launched a collaborative
multi-site international trial of the alternative tests.